Drugs / HV-101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05868915 | Aug 2023 → May 2025 | cancer | Hervor Therapeutics | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2020-11-19 | GH Research Ireland Limited | Results GH Research Ltd. Announces Completion of Phase 1 Clinical Study with GH001 (5-Methoxy-N,N-Dimethyltryptamine) in Healthy Volunteers and Updates on Further Progress ghres.com ↗
In the completed Phase 1 healthy volunteer study (GH001-HV-101), GH001 was safe and well-tolerated at the investigated dose levels. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2020-11-19 | GH Research Ireland Limited | GH Research Ltd. Announces Completion of Phase 1 Clinical Study with GH001 (5-Methoxy-N,N-Dimethyltryptamine) in Healthy Volunteers and Updates on Further Progress ghres.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HV-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05868915 ↗ |
| Modality | Cell therapy | “HV-101 is autologous tumor-infiltrating lymphocyte cells without genetic modification.” NCT05868915 ↗ |